Previous studies demonstrated that mutations in the KRAS proto-oncogene are responsible for 10–30 % of lung adenocarcinomas, while mutations and amplification of EGFR are common in NSCLC and provide the basis for treatment with EGFR-inhibitors [7]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.